| Drug Name |
Eflornithine hydrochloride |
| Drug ID |
BADD_D00752 |
| Description |
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines. |
| Indications and Usage |
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth). |
| Marketing Status |
approved; withdrawn |
| ATC Code |
D11AX16; P01CX03 |
| DrugBank ID |
DB06243
|
| KEGG ID |
D00829
|
| MeSH ID |
D000518
|
| PubChem ID |
57004
|
| TTD Drug ID |
D0X7JR
|
| NDC Product Code |
0023-4857; 54245-3110; 82160-125; 65129-3110 |
| UNII |
4NH22NDW9H
|
| Synonyms |
Eflornithine | DL-alpha-Difluoromethylornithine | DL alpha Difluoromethylornithine | alpha-Difluoromethylornithine | alpha Difluoromethylornithine | alpha-Difluoromethyl Ornithine | Ornithine, alpha-Difluoromethyl | alpha Difluoromethyl Ornithine | Difluoromethylornithine | MDL-71,782 A | MDL 71,782 A | MDL71,782 A | Ornidyl | Vaniqa | Eflornithine Monohydrochloride, Monohydrate | Eflornithine Hydrochloride | RMI 71782 |
